- Global Pharma News & Resources

AscellaHealth Offers Home Infusion Pharmacy Network, Complements Site of Care Optimization and Overall Strategy to Cut Costs While Ensuring Care Quality

BERWYN, Pa.--(BUSINESS WIRE)--AscellaHealth, a global specialty pharmacy and healthcare solutions company, is pleased to announce the release of its white paper, “Site of Care Optimization Lowers Specialty Drug Costs, Reduces Hospital Visits, Ensures Care Quality,” which articulates the value of Site of Care (SOC) optimization for infusion therapies, a leading strategy for reducing the cost of specialty biologic medications, improving outcomes and extending AscellaHealth’s commitment to patient-centric care by offering enhanced access to more convenient, quality-focused settings. Specialty products include a wide range of components, such as vaccines, blood and blood components, allergenics, somatic cells, gene/cell therapy, tissues and recombinant therapeutic proteins.

“Recognizing the importance of SOC optimization, AscellaHealth offers a Home Infusion Pharmacy Network as part of our overall strategy to cut costs without compromising quality of care,” says Dea Belazi, president and CEO, AscellaHealth. “Our pharmacy providers were chosen for their national reach, high-touch capabilities and thorough home infusion expertise, enabling care delivery in the highest-quality, lowest-cost care settings and enhancing outcomes via increased compliance rates.”

These select providers, including Amber Specialty Pharmacy, AcariaHealth and BioMatrix Specialty Pharmacy, can improve drug affordability for patients and providers, increase price transparency and reduce disparities in quality of care and safety.

Specialty drugs are used to treat complex, chronic or rare conditions and require special administration or handling with infusion therapies. These therapies involve the administration of medication through an intravenous needle or catheter, while others are administered via alternate routes of administration, such as intramuscular, epidural and self-injectable means.

“The exact same medications, administered using the same method, can be more than two-to-three times more expensive in the hospital setting vs. a stand-alone infusion center,” continues Belazi. “Insurance companies, self-funded companies and other stakeholders will find significant value in applying a high level of expertise to the management of these specialty drugs by working with AscellaHealth and its partners in SOC optimization. Flexibility of alternate sites also contributes to a higher quality of life by improving patient access to care, reducing time away from work or school, and offering a degree of independence to patients living under otherwise rigid medical parameters.”

About AscellaHealth LLC
AscellaHealth is a global Specialty Pharmacy and Healthcare services organization serving patients, payers, life sciences and providers, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and medical management services. An Inc. 5000 2021 winner, AscellaHealth’s unique, patient-centric approach supports its strategic partnership with Optime Care and is built upon proprietary technology processes for innovative programs and services optimizing health outcomes and quality of life for patients with complex chronic conditions or rare diseases that require specialty medications and/or gene and cell therapies. Visit


Nicole Dufour
CPR Communications
201.641.1911 x 54

Editor Details

  • Company:
    • Businesswire
Last Updated: 08-Feb-2022